For commercial breeding programmes, the discussion around SNP array vs genotyping by sequencing has evolved considerably. The challenge is no longer generating more markers. Most breeding organisations already have access to vast quantities of genomic data. The real challenge is generating the right information quickly enough to support advancement decisions, marker-assisted selection strategies, genomic selection pipelines and breeding programme optimisation.
Whether supporting marker-assisted selection, genomic selection, parentage QC, trait introgression, or other targeted breeding applications, organisations increasingly require genotyping workflows that can evolve alongside breeding objectives. New trait markers emerge, genomic prediction models improve and breeding priorities shift. Under these conditions, flexibility can be just as important as throughput and enables futureproofing genotyping screening strategies.
When evaluating Amplicon Sequencing, microarray vs NGS technologies or broader SNP array vs sequencing strategies, breeders should consider not only assay costs but also how effectively a platform supports long-term programme efficiency, breeding-cycle timelines and genetic gain.
:quality(75))
:quality(75))